Skip to main content

Agendia Nabs $23M Series E Financing

NEW YORK (GenomeWeb News) – Dutch molecular diagnostics firm Agendia said today that it has raised $23 million in a Series E investment round.

The financing was led by an undisclosed family investment firm that provided approximately half of the funds, Agendia said. In addition, two independent entrepreneurs participated with an investment of US $1 million each, while the remaining capital was raised through Agendia's existing investor base.

"The success of this financing round was aided by MammaPrint's increasing US demand, as well as growing reimbursement from private US payors," Bernhard Sixt, president and CEO of Agendia, said in a statement. "The proceeds will be used to accelerate the commercialization of MammaPrint in the US market."

Agendia received US Food and Drug Administration clearance two years ago for MammaPrint, its array-based breast cancer diagnostic test. It has since been working with reference centers in the US to help drive adoption of the test.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.